(Q44575051)

4 December 2017

Psoriasis triggered by infliximab in a patient with Behçet's disease (English)

1 reference

4 December 2017

0 references

Yuko Kawazoe

1

1 reference

4 December 2017

Sunao Sugita

2

1 reference

4 December 2017

Yukiko Yamada

3

1 reference

4 December 2017

Ai Akino

4

1 reference

4 December 2017

Keiko Miura

5

1 reference

4 December 2017

Manabu Mochizuki

6

1 reference

4 December 2017

23 October 2012

1 reference

Japanese Journal of Ophthalmology

4 December 2017

1 reference

4 December 2017

57

1 reference

4 December 2017

1

1 reference

4 December 2017

95-97

1 reference

https://scigraph.springernature.com/pub.10.1007/s10384-012-0198-4

4 December 2017

0 references

cites work

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS10384-012-0198-4

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-012-0198-4

Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-012-0198-4

Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-012-0198-4

New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-012-0198-4

Development of new-onset psoriasis while on anti-TNFalpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-012-0198-4

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-012-0198-4

Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy

21 January 2018

1 reference

12 December 2020

Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis

1 reference

12 December 2020

Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies

1 reference

12 December 2020

Acquired resistance to infliximab against uveitis due to Behçet's disease after one year of administration

1 reference

12 December 2020

Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab

1 reference

12 December 2020

Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction

1 reference

12 December 2020

Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis

1 reference

12 December 2020

10.1007/S10384-012-0198-4

Identifiers

DOI

1 reference

4 December 2017

1 reference